Journal Article

Efficacy and tolerability of subcutaneous repository corticotropin injection in refractory ocular inflammatory diseases

Yavari, Negin, Halim, Muhammad Sohail, Mobasserian, Azadeh, Or, Christopher, Le, Anthony, Feky, Dalia El, Saengsirinavin, Aim-On, Akhavanrezayat, Amir, Than, Ngoc Trong Tuong, Nguyen, Quan Dong, Ghoraba, Hashem, Anover, Frances Andrea, Mohammadi, S. Saeed, Gupta, Ankur Sudhir, Khatri, Anadi, Karaca, Irmak, Yoo, Woong Sun, Thng, Zheng Xian, Lyu, Xun, Elaraby, Osama, Jison, Louis A, Zhang, Xiaoyan

2024

Overview

BackgroundRepository corticotropin injection (RCI) has been suggested to exert immunomodulatory and anti-inflammatory effects in ocular inflammation. The index retrospective study aimed to evaluate the efficacy and tolerability of subcutaneous RCI in patients with active scleritis or uveitis.Main bodyMedical records of patients who were diagnosed with different types of active scleritis or uveitis and received RCI for more than six months at a tertiary eye center were reviewed. Patient characteristics including age, sex, comorbidities, clinical findings, treatment details, and adverse events were recorded. A total of 17 eyes of 17 patients were included. Median age was 43 years old and 53% of patients were male. Mean treatment duration was 25.4 ± 15.5 months. Indications for RCI therapy were scleritis (7 anterior and 1 posterior) (47.8%), panuveitis (17.4%), retinal vasculitis (17.4%), chronic/recurrent anterior uveitis (13%), and posterior uveitis (4.35%). RCI was initiated at a dose of 40 to 80 units 3 times weekly. Given the adequate control of inflammation, RCI was successfully discontinued in four patients (23.5%). Prior to RCI therapy, 14 (82.3%) patients were on oral prednisone at an average of 10 mg daily (range 2.5–40 mg), and two (11.7%) patients discontinued prednisone immediately before initiating RCI due to side effects. After six months of therapy, the prednisone dose was reduced in four (23.5%) patients to an average of 3 mg daily (range 1–5 mg) and was stopped in eight (53%) patients. Concomitant immunomodulatory therapies (IMTs) included mycophenolate mofetil (23.5%) and methotrexate (23.5%), and adalimumab (23.5%). Ten patients were on IMTs prior to using RCI, and during the course of treatment, IMT was stopped in two patients and reduced in one. Side effects included insomnia (23%), hypertension (11.7%), lower extremity edema (11.7%), hyperglycemia (11.7%), weight gain (11.7%), and infection (5.8%).ConclusionRCI may be considered as a potential therapy with acceptable tolerability for patients with non-infectious scleritis or uveitis.

• Publisher: Springer Nature B.V
• Subject: Drug dosages / Edema / Hyperglycemia / Hypertension / Infections / Inflammation / Inflammatory diseases / Insomnia / Monoclonal antibodies / Patients / Side effects / Statistical analysis / Steroids